A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 May 2014
At a glance
- Drugs Enokizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors MedImmune
- 31 Aug 2018 Biomarkers information updated
- 21 Nov 2007 Status changed from in progress to completed.
- 24 Dec 2005 New trial record.